CN103284958B - A kind of Cefdinir composition granule and preparation method thereof - Google Patents
A kind of Cefdinir composition granule and preparation method thereof Download PDFInfo
- Publication number
- CN103284958B CN103284958B CN201310248312.XA CN201310248312A CN103284958B CN 103284958 B CN103284958 B CN 103284958B CN 201310248312 A CN201310248312 A CN 201310248312A CN 103284958 B CN103284958 B CN 103284958B
- Authority
- CN
- China
- Prior art keywords
- cefdinir
- sucrose
- hpmc
- ethanol
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- RTXOFQZKPXMALH-GHXIOONMSA-N cefdinir Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-GHXIOONMSA-N 0.000 title claims abstract description 66
- 229960003719 cefdinir Drugs 0.000 title claims abstract description 66
- 239000008187 granular material Substances 0.000 title claims abstract description 52
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 44
- 229930006000 Sucrose Natural products 0.000 claims abstract description 36
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 36
- 239000005720 sucrose Substances 0.000 claims abstract description 36
- 229920000881 Modified starch Polymers 0.000 claims abstract description 22
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 22
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 22
- 239000004615 ingredient Substances 0.000 claims abstract description 17
- 238000005550 wet granulation Methods 0.000 claims description 8
- 238000007605 air drying Methods 0.000 claims description 7
- 239000012467 final product Substances 0.000 claims description 7
- 239000007779 soft material Substances 0.000 claims description 7
- 238000004090 dissolution Methods 0.000 abstract description 11
- 239000003814 drug Substances 0.000 abstract description 10
- 230000007774 longterm Effects 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 4
- 238000003860 storage Methods 0.000 abstract description 3
- 239000000047 product Substances 0.000 description 22
- 238000012360 testing method Methods 0.000 description 17
- 239000013068 control sample Substances 0.000 description 12
- 239000000126 substance Substances 0.000 description 9
- 239000000523 sample Substances 0.000 description 8
- 238000012552 review Methods 0.000 description 5
- 238000005070 sampling Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000013558 reference substance Substances 0.000 description 4
- 229930186147 Cephalosporin Natural products 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 229940124587 cephalosporin Drugs 0.000 description 3
- 150000001780 cephalosporins Chemical class 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Abstract
The present invention relates to field of medicine preparations, specifically disclose a kind of Cefdinir composition granule and preparation method thereof.Cefdinir composition granule effective ingredient of the present invention comprises cefdinir, pregelatinized starch, 50% ethanol, HPMC, sucrose.The preferred cefdinir of the present invention, pregelatinized starch, 50% ethanol, HPMC, sucrose are as the effective ingredient of cefdinir granules, mutual synergism improves stability and the dissolution of cefdinir, and mouthfeel is better than existing product, improve the compliance of patient medication, be conducive to safe handling and the long term storage of clinical medicine.
Description
Technical field
The present invention relates to field of medicine preparations, be specifically related to a kind of Cefdinir composition granule and preparation method thereof.
Background technology
Cefdinir; English Cefdinir Capsules by name; chemistry (6R by name; 7R)-7-[[(2-amino-4-thiazolyl)-(oximido) acetyl group] is amino]-3-vinyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylic acid, chemical constitution is as follows:
Cefdinir belongs to semisynthetic, the oral third generation cephalosporin of wide spectrum, and its synthesis by anti-bacteria cell wall produces antibacterial action.This product all has antibacterial activity to gram positive bacteria and negative bacterium, and stablizes most of beta-lactamase, so the microorganism of many penicillin resistants and cephalosporin is responsive to this product.Clinically be used for the treatment of tonsillitis, sinusitis, otitis media, acute bronchitis, pneumonia, abdominal cavity, urogenital infections etc.
Cefdinir raw material is micro-yellow powder shape, and poorly water-soluble, easily produces electrostatic, poor fluidity, and unstable under hot and humid condition, and related substance raises, and affects its safety and effectiveness.Therefore, suitable appropriate drug component just becomes the key factor affecting cefdinir preparation quality, develops a kind of cefdinir granule be made up of phase suitable drugs component and can bring positive effect for the safe and effective application of cefdinir undoubtedly.As patent CN201010176154.8 discloses a kind of cephalosporin suspension granule and preparation method thereof, which employs active component, stabilizing agent, excipient, suspending agent, disintegrating agent, correctives coloring agent binding agent, spice various ingredients, wherein embodiment 4 specifically discloses a kind of technical scheme of cefdinir mix suspension grain, although can bring certain improvement for cefdinir preparation quality, too much compositional selecting also becomes the not high influence factor of cefdinir stability, dissolution.
Summary of the invention
In view of this, the object of the present invention is to provide a kind of Cefdinir composition granule and preparation method thereof, make described cefdinir granules can improve stability (as the aspect such as labelled amount, related substance) and the dissolution of cefdinir.
For achieving the above object, the invention provides following technical scheme:
A kind of Cefdinir composition granule, effective ingredient comprises cefdinir, pregelatinized starch, 50% ethanol, HPMC, sucrose.
As preferably, with parts by weight, described effective ingredient comprises 40-100 part cefdinir, 5-20 part pregelatinized starch, 50-70 part 50% ethanol, 15-20 part HPMC, 400-450 part sucrose.
More preferably, described effective ingredient comprises 50 parts of cefdinirs, 5 parts of pregelatinized starchs, 60 part of 50% ethanol, 20 portions of HPMC, 430 portions of sucrose.
For existing cefdinir granules stability and the not high defect of dissolution, particularly in the labelled amount, related substance equistability of long term storage and extreme environment, the present invention is through long-term further investigation, consider the impact between various effective ingredient, optimize the compositing formula of cefdinir granules, select cefdinir, pregelatinized starch, 50% ethanol, HPMC, sucrose as effective ingredient, improve its stability under hot and humid environment and dissolution.
The various components that the present invention adopts, not only synergism adds the stability of cefdinir granules, and it also has some advantages separately, if starch is the nutrient substance of needed by human.Under the effect of the digestive enzyme in human body, starch can become glucose molecule gradually.Glucose has critical role in field of biology, energy source and the metabolism intermediate product of living cells, it is that one can directly absorb, supplement the carbohydrate of heat energy, it is the main source of needed by human body energy, be oxidized to carbon dioxide and water in vivo, and supply heat simultaneously, or store with glycogen form.The function of detoxification of liver can be promoted, have protective effect to liver.Energy goods and materials the most common in organism.Pregelatinized starch is compared with native starch, and it has many advantages: 1. good fluidity, and no matter be dry or wet, mobility is all fine, and has bonding and disintegrating property concurrently.2. compressibility is good, is applicable to direct compression of full-powder.3. there is self-lubrication, reduce the strength that tablet ejects from mould circle.4. good disintegrative.5. to the solubility of portion of cold water.6. inoperative with principal agent, and have the function of stable medicine, easily cause variable color to wet, heat sensitive medicine such as the wet granulation such as vitamin C, aspirin, content and drug effect decline, and after using this product instead, facilitate the stability of principal agent, extend useful life.
Sucrose is a kind of natural organic matter, and sucrose extracts from sugar crop Radix Betae or Caulis Sacchari sinensis, and the end product that people eats rear decomposition is carbon dioxide and water.Sucrose has unique function, and the sweet taste as sucrose is pure stable, is easy to dissolve and toning, can also crystallizes out rapidly from saturated solution; Sucrose has osmosis, and harmful microbe can be suppressed to grow; Sucrose has water absorption and water-retaining property.Sucrose in Cefdinir composition granule of the present invention is with low cost, but also granule can be made to have good water absorption and water-retaining property.
In addition, the present invention also provides a kind of preparation method of Cefdinir composition granule, with cefdinir, pregelatinized starch, 50% ethanol, HPMC, sucrose for effective ingredient, cefdinir is crossed 120 mesh sieves for subsequent use, it is for subsequent use that 80 orders pulverized by sucrose; Take cefdinir, pregelatinized starch, HPMC, sucrose fully mixes, with 50% ethanol soft material, 20 order wet granulations, by granule about 65 DEG C forced air dryings, dry granule 16 order granulate, sieve 80 orders and get final product.
As preferably, with parts by weight, each effective ingredient content is:
40-100 part cefdinir, 5-20 part pregelatinized starch, 50-70 part 50% ethanol, 15-20 part HPMC, 400-450 part sucrose.
More preferably, with parts by weight, each effective ingredient content is:
50 parts of cefdinirs, 5 parts of pregelatinized starchs, 60 part of 50% ethanol, 20 portions of HPMC, 430 portions of sucrose.
Product disclosed in prepared Cefdinir composition granule and CN201010176154.8 patent is carried out high humidity high temperature exposure experiments to light, accelerated test and long term test by the present invention, result shows, when accelerated test and long term test, the indexs such as principal agent labelled amount and related substance are more stable, compared with the control sample prepared with prior art, the present invention's amplitude of variation in every respect is all less than the amplitude of variation of control sample, and stability is stronger.Meanwhile, result also shows product dissolution of the present invention higher than control sample.Thus, the present invention also provides a kind of Cefdinir composition granule prepared by preparation method of the present invention.
From above technical scheme, the preferred cefdinir of the present invention, pregelatinized starch, 50% ethanol, HPMC, sucrose are as the effective ingredient of cefdinir granules, mutual synergism improves stability and the dissolution of cefdinir, and mouthfeel is better than existing product, improve the compliance of patient medication, be conducive to safe handling and the long term storage of clinical medicine.
Detailed description of the invention
The invention discloses a kind of Cefdinir composition granule and preparation method thereof, those skilled in the art can use for reference present disclosure, and suitable improving technique parameter realizes.Special needs to be pointed out is, all similar replacements and change apparent to those skilled in the art, they are all deemed to be included in the present invention.The method of the invention is described by preferred embodiment, related personnel obviously can not depart from content of the present invention, spirit and scope compound as herein described and preparation method are changed or suitably change with combination, realize and apply the technology of the present invention.
In the present invention, the amount of all cefdinirs is all with C
14h
13n
5o
5s
2meter.Below in conjunction with embodiment, set forth the present invention further.
Embodiment 1: prepare Cefdinir composition granule of the present invention
Cefdinir is crossed 120 mesh sieves for subsequent use, it is for subsequent use that 80 orders pulverized by sucrose; Take cefdinir, pregelatinized starch, HPMC, sucrose fully mixes, with 50% ethanol soft material, 20 order wet granulations, by granule about 65 DEG C forced air dryings, dry granule 16 order granulate, sieve 80 orders, and middle product detect, subpackage and get final product.
Embodiment 2: prepare Cefdinir composition granule of the present invention
Cefdinir is crossed 120 mesh sieves for subsequent use, it is for subsequent use that 80 orders pulverized by sucrose; Take cefdinir, pregelatinized starch, HPMC, sucrose fully mixes, with 50% ethanol soft material, 20 order wet granulations, by granule about 65 DEG C forced air dryings, dry granule 16 order granulate, sieve 80 orders, and middle product detect, subpackage and get final product.
Embodiment 3: prepare Cefdinir composition granule of the present invention
Cefdinir is crossed 120 mesh sieves for subsequent use, it is for subsequent use that 80 orders pulverized by sucrose; Take cefdinir, pregelatinized starch, HPMC, sucrose fully mixes, with 50% ethanol soft material, 20 order wet granulations, by granule about 65 DEG C forced air dryings, dry granule 16 order granulate, sieve 80 orders, and middle product detect, subpackage and get final product.
Embodiment 4: prepare Cefdinir composition granule of the present invention
Cefdinir is crossed 120 mesh sieves for subsequent use, it is for subsequent use that 80 orders pulverized by sucrose; Take cefdinir, pregelatinized starch, HPMC, sucrose fully mixes, with 50% ethanol soft material, 20 order wet granulations, by granule about 65 DEG C forced air dryings, dry granule 16 order granulate, sieve 80 orders, and middle product detect, subpackage and get final product.
Embodiment 5: preparation contrast Cefdinir composition granule
Cefdinir is crossed 120 mesh sieves for subsequent use, it is for subsequent use that 80 orders pulverized by sucrose; Take cefdinir, HPMC, sucrose fully mixes, with 50% ethanol soft material, 20 order wet granulations, by granule about 65 DEG C forced air dryings, dry granule 16 order granulate, sieve 80 orders, and middle product detect, subpackage and get final product.
Embodiment 6: Product checking result
Get embodiment of the present invention 1-4 sample and embodiment 5 sample (reference substance 1), CN201010176154.8 patent Example 4 product (reference substance 2), carry out Product checking, the results are shown in Table 1.
Table 1 Product checking result
As seen from the above table, product prepared by the present invention is before the test not carrying out various extreme environment, its testing result such as stability and dissolution and existing reference substance no significant difference, and mouthfeel is better than reference substance, add the compliance that patient takes, show that cefdinir granules quality prepared by the present invention meets existing standard.
Embodiment 7: high temperature, high humidity, exposure experiments to light
Get the embodiment of the present invention 4 sample and embodiment 5 sample (control sample 1), CN201010176154.8 patent Example 4 product (control sample 2), put respectively in the container of sealing clean, carry out high temperature, high humidity, exposure experiments to light, experimental condition is as follows:
High temperature: place 10 days at 60 DEG C of temperature, in the 5th day and sampling in the 10th day, detect by stability high spot reviews project, result of the test compared with 0 day.
High humidity: place 10 days under 25 DEG C of conditions respectively at relative humidity 90% ± 5%, in the 5th day and sampling in the 10th day, detect by stability high spot reviews project, result of the test compared with 0 day.
Illumination: being placed in illumination is place 10 days under the condition of 4500Lx, and in the 5th day and sampling in the 10th day, detect by stability high spot reviews project, result of the test compared with 0 day.
Testing result is in table 2
The hot and humid exposure experiments to light testing result of table 2
As can be seen from table 2 data, the embodiment of the present invention 4 product, under high temperature, high humidity, illumination condition, all will be stablized than control sample in moisture, dissolution, related substance and labelled amount etc.
Embodiment 8: accelerated test
Get the embodiment of the present invention 4 sample and embodiment 5 sample (control sample 1), CN201010176154.8 patent Example 4 product (control sample 2), place 6 months under temperature 40 DEG C ± 2 DEG C, relative humidity are the condition of 75% ± 5% respectively, respectively at the 1st, 2,3,6 sampling at the end of month once, measure by stability high spot reviews project.Result of the test is in table 3.
Table 3 accelerated test result
As can be seen from table 3 data, the embodiment of the present invention 3 product, under temperature 40 DEG C ± 2 DEG C, relative humidity are the condition of 75% ± 5%, all will be stablized than control sample in moisture, dissolution, related substance and labelled amount etc.
Embodiment 9: long term test
Get the embodiment of the present invention 4 sample and embodiment 5 sample (control sample 1), CN201010176154.8 patent Example 4 product (control sample 2), it is 20 DEG C in temperature respectively, relative humidity is place 12 months under the condition of 60% ± 10%, respectively at the 3rd, 6,9,12 sampling at the end of month once, measure by stability high spot reviews project.Result of the test is in table 4.
Table 4 long-term test results
As can be seen from table 4 data, the embodiment of the present invention 4 product is 20 DEG C in temperature, and relative humidity is under the condition of 60% ± 10%, all will stablize than control sample in moisture, dissolution, related substance and labelled amount etc.
The above is only the preferred embodiment of the present invention; it should be pointed out that for those skilled in the art, under the premise without departing from the principles of the invention; can also make some improvements and modifications, these improvements and modifications also should be considered as protection scope of the present invention.
Claims (5)
1. a Cefdinir composition granule, it is characterized in that, with parts by weight, described effective ingredient is made up of 40-100 part cefdinir, 5-20 part pregelatinized starch, 50-70 part 50% ethanol, 15-20 part HPMC, 400-450 part sucrose.
2. Cefdinir composition granule according to claim 1, it is characterized in that, with parts by weight, described effective ingredient is made up of 50 parts of cefdinirs, 5 portions of pregelatinized starchs, 60 part of 50% ethanol, 20 portions of HPMC, 430 portions of sucrose.
3. the preparation method of a Cefdinir composition granule, it is characterized in that, with cefdinir, pregelatinized starch, 50% ethanol, HPMC, sucrose for effective ingredient, cefdinir is crossed 120 mesh sieves for subsequent use, it is for subsequent use that 80 orders pulverized by sucrose; Take cefdinir, pregelatinized starch, HPMC, sucrose fully mixes, with 50% ethanol soft material, 20 order wet granulations, by granule about 65 DEG C forced air dryings, dry granule 16 order granulate, sieve 80 orders and get final product;
Each effective ingredient content is:
40-100 part cefdinir, 5-20 part pregelatinized starch, 50-70 part 50% ethanol, 15-20 part HPMC, 400-450 part sucrose.
4. preparation method according to claim 3, it is characterized in that, with parts by weight, each effective ingredient content is:
50 parts of cefdinirs, 5 parts of pregelatinized starchs, 60 part of 50% ethanol, 20 portions of HPMC, 430 portions of sucrose.
5. the Cefdinir composition granule that described in claim 3-4 any one prepared by preparation method.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310248312.XA CN103284958B (en) | 2013-06-21 | 2013-06-21 | A kind of Cefdinir composition granule and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310248312.XA CN103284958B (en) | 2013-06-21 | 2013-06-21 | A kind of Cefdinir composition granule and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103284958A CN103284958A (en) | 2013-09-11 |
| CN103284958B true CN103284958B (en) | 2015-07-29 |
Family
ID=49086856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310248312.XA Active CN103284958B (en) | 2013-06-21 | 2013-06-21 | A kind of Cefdinir composition granule and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103284958B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103637992B (en) * | 2013-12-19 | 2015-04-08 | 石家庄市华新药业有限责任公司 | Cefdinir granular preparation and preparation method thereof |
| CN115607553B (en) * | 2021-07-16 | 2024-02-23 | 广州白云山天心制药股份有限公司 | Medicine containing cefdinir |
| CN114983964A (en) * | 2022-06-24 | 2022-09-02 | 广东恒健制药有限公司 | Cefdinir granules and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101816635A (en) * | 2010-05-17 | 2010-09-01 | 广东恒健制药有限公司 | Cephalosporin suspension granule and preparation method thereof |
| CN102058561A (en) * | 2010-12-30 | 2011-05-18 | 江苏亚邦强生药业有限公司 | Cefdinir capsule and preparation method thereof |
| CN102266306A (en) * | 2011-07-13 | 2011-12-07 | 石家庄四药有限公司 | Cefdinir capsules and preparation method thereof |
-
2013
- 2013-06-21 CN CN201310248312.XA patent/CN103284958B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101816635A (en) * | 2010-05-17 | 2010-09-01 | 广东恒健制药有限公司 | Cephalosporin suspension granule and preparation method thereof |
| CN102058561A (en) * | 2010-12-30 | 2011-05-18 | 江苏亚邦强生药业有限公司 | Cefdinir capsule and preparation method thereof |
| CN102266306A (en) * | 2011-07-13 | 2011-12-07 | 石家庄四药有限公司 | Cefdinir capsules and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 周永健等.第三代口服头孢菌素-头孢地尼.《天津药学》.2003,第15卷(第2期),第66-68页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103284958A (en) | 2013-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101816635B (en) | Cephalosporin suspension granule and preparation method thereof | |
| CN103349646B (en) | A kind of pharmaceutical composition of cefaclor granule, its preparation method and application | |
| CN103284958B (en) | A kind of Cefdinir composition granule and preparation method thereof | |
| CN102525963B (en) | Netilmicin sulfate lyophiled powder injection and preparation method thereof | |
| CN101912368A (en) | Compound cefaclor suspension and preparation method thereof | |
| CN102286045B (en) | Roxithromycin monohydrate crystal, preparation method thereof and compound dry suspension containing roxithromycin monohydrate crystal and ambroxol hydrochloride composition | |
| CN103446075B (en) | A kind of Cefaclor Capsules and preparation method thereof | |
| CN103330685A (en) | Cefaclor granule and preparation method thereof | |
| CN103893132B (en) | A kind of cefdinir granules and preparation technology thereof | |
| CN103301075B (en) | A kind of cefixime composition mix suspension grain agent and preparation method thereof | |
| CN104688713A (en) | Cefradine capsule and preparation method thereof | |
| CN105534937A (en) | Cefadroxil tablet and preparation method thereof | |
| CN103622916B (en) | Cefixime dry suspension and preparation method thereof | |
| CN103919744B (en) | A kind of Cefteram Pivoxil Tablets and preparation technology thereof | |
| CN103520120B (en) | A kind of L-084 composition granule | |
| CN104546735A (en) | Pediatric tosufloxacin tosilate granule and preparation method thereof | |
| CN102342949B (en) | Application of phlorhizin in preparation of drug for treating hyperuricemia | |
| CN102311452A (en) | Cefixime crystal, preparation method thereof and tablet composition containing same | |
| CN103263398B (en) | Cefdinir composition capsule and preparation method thereof | |
| CN104382849B (en) | A kind of cefaclor dry suspension and preparation method thereof | |
| CN105496984A (en) | Cefixime capsule stable in quality and preparation method thereof | |
| CN106588954B (en) | A kind of anti-infectives amoxycillin crystalline compounds and combinations thereof | |
| CN109846827A (en) | A kind of Cefixime mix suspension grain agent and preparation method thereof | |
| CN104130303A (en) | Cobamamide compound and medicinal composition thereof | |
| CN104523688B (en) | Ampicillin and probenecid capsules and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: SHANDONG LUOXIN PHARMACY GROUP CO., LTD. Free format text: FORMER OWNER: SHANDONG LUOXIN PHARMACY STOCK CO., LTD. Effective date: 20150630 Owner name: SHANDONG YUXIN PHARMACEUTICAL CO., LTD. SHANDONG H Effective date: 20150630 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Han Houliang Inventor after: Zhang Zonglin Inventor after: Li Mingjie Inventor after: Wang Jinxing Inventor after: Liu Yanzhen Inventor before: Zhang Zonglin Inventor before: Li Mingjie Inventor before: Wang Jinxing Inventor before: Liu Yanzhen |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: ZHANG ZONGLIN LI MINGJIE WANG JINXING LIU YANZHEN TO: HAN HOULIANG ZHANG ZONGLIN LI MINGJIE WANG JINXING LIU YANZHEN |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20150630 Address after: Seven of 276017 Shandong province Linyi city Luozhuang District No. 18 Applicant after: Shandong Luo Xin Pharmaceutical Group Plc Applicant after: Shandong Yu Xin pharmaceutcal corporation, Ltd Applicant after: SHANDONG HENGXIN PHARMACEUTICAL CO., LTD. Address before: Seven of 276017 Shandong province Linyi city Luozhuang District No. 18 Applicant before: SHANDONG LUOXIN PHARMACY STOCK Co., LTD. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 276017 18 Luo Qi Road, Luozhuang District, Linyi, Shandong Co-patentee after: Shandong Yu Xin pharmaceutcal corporation, Ltd Patentee after: Shandong Luo Xin Pharmaceutical Group Plc Co-patentee after: Shandong Luoxin Pharmaceutical Group Hengxin Pharmacy Co., Ltd. Address before: 276017 18 Luo Qi Road, Luozhuang District, Linyi, Shandong Co-patentee before: Shandong Yu Xin pharmaceutcal corporation, Ltd Patentee before: Shandong Luo Xin Pharmaceutical Group Plc Co-patentee before: SHANDONG HENGXIN PHARMACEUTICAL CO., LTD. |